<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937556</url>
  </required_header>
  <id_info>
    <org_study_id>COV/21.02</org_study_id>
    <nct_id>NCT04937556</nct_id>
  </id_info>
  <brief_title>Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).</brief_title>
  <acronym>PROVID</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of the Lactobacillus Probiotic Strain in the Immune Response in Participants Positive for SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2) Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProbiSearch SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProbiSearch SL</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional, randomized, double-blind, placebo-controlled study will be conducted to&#xD;
      investigate the effect of a probiotic strain on the immune response in participants positive&#xD;
      for SARS-CoV-2 infection.&#xD;
&#xD;
      The study duration will be 28 days, which includes 4 weeks product administration.&#xD;
      Participants will be randomized assigned to one of the two study groups: the control group&#xD;
      with placebo consumption and a probiotic consumption group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of specific IgM (Immunoglobulin M) and IgG (Immunoglobulin G) antibodies for the SARS-CoV-2 virus.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels (pg/ml) of pro-inflammatory and anti-inflammatory markers in blood serum.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the symptoms produced by the SARS-CoV-2 infection</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms produced during SARS-CoV-2 infection</measure>
    <time_frame>1 month</time_frame>
    <description>Severity of symtoms will be analysed for fever (Tª&gt;38ºC) and gastrointestinal symptons (Bristol scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a negative result in the SARS-CoV-2 detection test by PCR (Polymerase Chain Reaction) at visit 2</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with worsening of lower respiratory tract infections</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Probiotic: Lactobacillus salivarius + Vit D + Zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactobacillus strain during 28 days, approximately 1*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo supplement in 1 capsule per day during 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic: Lactobacillus salivarius + Vit D + Zinc</intervention_name>
    <description>A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.</description>
    <arm_group_label>Probiotic: Lactobacillus salivarius + Vit D + Zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in 1 capsule will be daily administrated during 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (18-65 years).&#xD;
&#xD;
          -  Mild infection by SARS-CoV-2 detected by PCR or Antigen.&#xD;
&#xD;
          -  Onset of COVID-19 symptoms up to 5 days before the day of inclusion&#xD;
&#xD;
          -  Without hospitalization or oxygen supplementation on the day of inclusion.&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious SARS-CoV-2 infection requiring hospitalization or oxygen supply&#xD;
&#xD;
          -  Chronic diseases under regular medication (eg asthma, allergic rhinitis ...)&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency&#xD;
&#xD;
          -  Body Mass Index (BMI)&gt; 30&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Short bowel syndrome or any surgery on the gastrointestinal tract.&#xD;
&#xD;
          -  Metabolic disorders (diabetes, etc.).&#xD;
&#xD;
          -  Heart failure and cardiac medical history&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  History of significant gastrointestinal diseases&#xD;
&#xD;
          -  Use of other probiotics during the last month.&#xD;
&#xD;
          -  Uncertainty about the willingness or ability of the participant to comply with the&#xD;
             requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SUSANA MANZANO, PhD</last_name>
    <phone>918035179</phone>
    <email>susana.manzano@probisearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SERGIO IGLESIAS, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.probisearch.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

